Memphasys expands into UAE market

Memphasys (ASX:MEM) has received an order for its Felix™ System from a clinic in Dubai, UAE. The order, facilitated by UAE distributor Panacea Medizintech LLC, includes a demonstration unit and 30 cartridges for research purposes under MOHAP guidelines. This move is a significant exploration of the system's potential in the UAE market.

Market potential and strategic ambitions

Memphasys is targeting the UAE's advanced medical technology market with its Felix™ System, leveraging the region's growth in IVF due to rising infertility rates. The UAE's position as a medical tourism hub enhances the potential adoption of the Felix™ System. Memphasys is focusing on regulatory compliance and strategic expansion within the Middle Eastern market. The company's ambitions include obtaining global regulatory clearances and optimizing the commercial roll-out of the Felix™ System, as part of its broader strategy to expand its global presence in reproductive biotechnology.

Executive insights on new order

Dr. David Ali, CEO and Managing Director of Memphasys, expressed enthusiasm about the order, highlighting the growing interest in the Felix™ System and its potential to meet the needs of key opinion leaders and clinics globally. Memphasys plans to work closely with Panacea Medizintech LLC throughout the evaluation process, aiming to optimize outcomes and contribute to the global expansion of the Felix™ System. The company is committed to advancing the development and commercialization of the Felix™ System in compliance with regulatory standards, including obtaining necessary certifications such as the CE Mark and TGA certification.